Salim Syed
Stock Analyst at Mizuho
(0)
# 4004
Out of 5,270 analysts
76
Total ratings
37.04%
Success rate
-5.30%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
WAVE Life Sciences | Maintains: Outperform | 19 22 | 10.09 | 118.04% | 5 | Nov 21, 2024 | |
Nkarta | Maintains: Outperform | 20 16 | 1.62 | 887.65% | 7 | Nov 21, 2024 | |
Gilead Sciences | Maintains: Outperform | 90 100 | 116.08 | -13.85% | 6 | Nov 21, 2024 | |
Cytokinetics | Maintains: Outperform | 99 103 | 42.92 | 139.98% | 6 | Nov 21, 2024 | |
Biogen | Maintains: Outperform | 251 207 | 141.77 | 46.01% | 15 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 113 163 | 72.02 | 126.33% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 25 18 | 7.04 | 155.68% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 223 235 | 310.8 | -24.39% | 7 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 34 | 19.64 | 73.12% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 82 99 | 42.26 | 134.26% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 60 53 | 32.95 | 60.85% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 6 | 1.55 | 287.1% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 21 | 1 | 2000% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 168 36 | 12.3 | 192.68% | 1 | Nov 16, 2022 |